Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

French (CAC) Pharma Industry Analysis

UpdatedJan 31, 2026
DataAggregated Company Financials
Companies6
  • 7D-0.1%
  • 3M-7.3%
  • 1Y-20.4%
  • YTD-1.8%

Over the last 7 days, the Pharma industry has dropped 2.9%, driven by Sanofi declining 3.4%. However, the industry is down 22% over the past year. Earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the French Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 31 Jan 2026€111.7b€53.8b€5.5b22.1x20.4x2.1x
Mon, 29 Dec 2025€113.8b€53.0b€7.0b22x16.3x2.1x
Wed, 26 Nov 2025€120.3b€53.0b€7.0b22.8x17.3x2.3x
Fri, 24 Oct 2025€120.1b€52.9b€6.9b22.3x17.4x2.3x
Sun, 21 Sep 2025€111.8b€52.8b€6.9b20.1x16.2x2.1x
Tue, 19 Aug 2025€118.1b€52.8b€6.9b19.4x17.1x2.2x
Thu, 17 Jul 2025€114.5b€52.1b€6.7b19.6x17.2x2.2x
Sat, 14 Jun 2025€118.5b€52.1b€6.7b18.3x17.8x2.3x
Mon, 12 May 2025€125.7b€52.1b€6.7b18.2x18.9x2.4x
Wed, 09 Apr 2025€126.2b€51.2b€5.9b17.5x21.2x2.5x
Fri, 07 Mar 2025€150.8b€51.1b€5.9b18.5x25.4x2.9x
Sun, 02 Feb 2025€144.4b€51.1b€6.3b19.2x23x2.8x
Tue, 31 Dec 2024€130.1b€55.2b€5.1b19.1x25.5x2.4x
Thu, 28 Nov 2024€129.2b€55.2b€5.1b19.4x25.4x2.3x
Sat, 26 Oct 2024€139.8b€53.8b€4.8b21.1x29.1x2.6x
Mon, 23 Sep 2024€144.2b€53.9b€4.8b20.5x30x2.7x
Wed, 21 Aug 2024€137.3b€53.8b€4.8b20.1x28.6x2.6x
Fri, 19 Jul 2024€129.5b€52.9b€5.2b21.9x25x2.4x
Sun, 16 Jun 2024€123.3b€52.9b€5.1b20.7x24x2.3x
Tue, 14 May 2024€130.7b€52.9b€5.2b20.8x25.3x2.5x
Thu, 11 Apr 2024€124.0b€52.7b€6.0b20.3x20.5x2.4x
Sat, 09 Mar 2024€123.1b€52.6b€6.0b20.3x20.4x2.3x
Mon, 05 Feb 2024€123.7b€53.0b€6.1b20.5x20.4x2.3x
Wed, 03 Jan 2024€128.4b€52.2b€9.7b19x13.2x2.5x
Fri, 01 Dec 2023€120.5b€52.2b€9.7b17.5x12.4x2.3x
Sun, 29 Oct 2023€115.6b€52.2b€9.7b15.2x11.9x2.2x
Tue, 26 Sep 2023€143.9b€52.6b€9.3b18.2x15.5x2.7x
Thu, 24 Aug 2023€139.1b€52.6b€9.3b21.3x15x2.6x
Sat, 22 Jul 2023€137.5b€52.6b€9.1b18.5x15x2.6x
Mon, 19 Jun 2023€133.9b€52.6b€9.1b15.6x14.6x2.5x
Wed, 17 May 2023€139.9b€52.6b€9.1b15.5x15.3x2.7x
Fri, 14 Apr 2023€141.0b€51.8b€9.2b15.2x15.4x2.7x
Sun, 12 Mar 2023€125.8b€51.7b€9.2b15.1x13.7x2.4x
Tue, 07 Feb 2023€119.8b€51.7b€7.7b18.2x15.6x2.3x
Price to Earnings Ratio

15.6x


Total Market Cap: €119.8bTotal Earnings: €7.7bTotal Revenue: €51.7bTotal Market Cap vs Earnings and Revenue0%0%0%
French Pharma Industry Price to Earnings3Y Average 19.4x202420252026
Current Industry PE
  • Investors are pessimistic on the French Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 15.7x which is lower than its 3-year average PE of 19.4x.
  • The 3-year average PS ratio of 2.4x is higher than the industry's current PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 3.1% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the French Healthcare industry?

FR Market-1.12%
Healthcare-2.53%
Pharma-0.12%
Pharma-0.12%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IPN Ipsen€137.600.7%
+€82.1m		15.4%PE25.2x
VETO Vetoquinol€86.903.0%
+€29.5m		22.4%PE17.1x
ALTHX THX Pharma Société Anonyme€2.5015.7%
+€4.7m		344.8%PS39.4x

Latest News

SAN
€79.20
Sanofi
7D
-0.1%
1Y
-24.1%
IPN
€137.60
Ipsen
7D
0.7%
1Y
15.4%

IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook

Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.
MEDCL
€22.56
MedinCell
7D
-22.7%
1Y
43.3%
VIRP
€351.50
Virbac
7D
-3.3%
1Y
8.5%

VIRP: Broad Regional Execution And 2026 Outlook Will Support Bullish Repricing

Narrative Update The analyst price target for Virbac has been raised from €390 to €415, with analysts citing accelerated growth across all regions as the key driver of this change. Analyst Commentary Analysts lifting their price target on Virbac to €415 from €390 are focusing on how the company is executing its growth plans across regions and what that could mean for valuation and risk.
EAPI
€2.12
Euroapi
7D
-2.6%
1Y
-34.4%

EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile

Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.
ALTHX
€2.50
THX Pharma Société Anonyme
7D
15.7%
1Y
344.8%
ALDVI
€1.67
Advicenne
7D
-2.8%
1Y
-16.5%
VETO
€86.90
Vetoquinol
7D
3.0%
1Y
22.4%
AB
€1.40
AB Science
7D
-2.2%
1Y
-9.7%
BOI
€29.90
Boiron
7D
-1.5%
1Y
13.0%

Is Boiron (EPA:BOI) Using Too Much Debt?

Dec 05
Is Boiron (EPA:BOI) Using Too Much Debt?